SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-027644
Filing Date
2023-06-13
Accepted
2023-06-13 13:00:39
Documents
12
Period of Report
2023-06-07
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K rare-20230607.htm   iXBRL 8-K 88371
  Complete submission text file 0000950170-23-027644.txt   203324

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rare-20230607_pre.xml EX-101.PRE 9457
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rare-20230607.xsd EX-101.SCH 2475
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rare-20230607_lab.xml EX-101.LAB 12806
6 EXTRACTED XBRL INSTANCE DOCUMENT rare-20230607_htm.xml XML 4516
Mailing Address 60 LEVERONI COURT NOVATO CA 94949
Business Address 60 LEVERONI COURT NOVATO CA 94949 415-483-8800
Ultragenyx Pharmaceutical Inc. (Filer) CIK: 0001515673 (see all company filings)

IRS No.: 272546083 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36276 | Film No.: 231010829
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences